Do analysts prefer ADXN or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ADXN or BPTH more profitable?

Addex Therapeutics' return on equity of -105.98% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -105.98% -87.61% Bio-Path N/A -2,842.40% -337.48%

Do analysts prefer BPTH or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 302.82%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, BPTH or CNSP?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is BPTH or CNSP more profitable?

CNS Pharmaceuticals' return on equity of -238.68% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% CNS Pharmaceuticals N/A -238.68% -166.30%

Do analysts prefer XBIO or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is XBIO or BPTH more profitable?

Bio-Path has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Xenetic Biosciences -70.03% -39.28% -33.47% Bio-Path N/A -2,842.40% -337.48%

Do analysts prefer TNFA or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, TNFA or BPTH?

Bio-Path is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is TNFA or BPTH more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% Bio-Path N/A -2,842.40% -337.48%

Which has stronger earnings and valuation, ACXP or BPTH?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is ACXP or BPTH more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Bio-Path N/A -2,842.40% -337.48%

Bio-Path (BPTH) Competitors

$0.04 0.00 (0.00%)

As of 06/12/2026 02:44 PM Eastern

Compare

BPTH vs. ADXN, CNSP, XBIO, TNFA, and ACXP

Should you buy Bio-Path stock or one of its competitors? MarketBeat compares Bio-Path with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Path include Addex Therapeutics (ADXN), CNS Pharmaceuticals (CNSP), Xenetic Biosciences (XBIO), TNF Pharmaceuticals (TNFA), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry.

How does Bio-Path compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, Addex Therapeutics had 3 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for Addex Therapeutics and 0 mentions for Bio-Path. Addex Therapeutics' average media sentiment score of 0.61 beat Bio-Path's score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Positive
Bio-Path	Neutral

Addex Therapeutics' return on equity of -105.98% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-105.98%	-87.61%
Bio-Path	N/A	-2,842.40%	-337.48%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Addex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Addex Therapeutics has higher revenue and earnings than Bio-Path. Addex Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	37.40	-$8.12M	-$5.74	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Summary

Addex Therapeutics beats Bio-Path on 10 of the 12 factors compared between the two stocks.

How does Bio-Path compare to CNS Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Bio-Path has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals had 3 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for Bio-Path. CNS Pharmaceuticals' average media sentiment score of 0.41 beat Bio-Path's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Path	Neutral
CNS Pharmaceuticals	Neutral

CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 302.82%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

CNS Pharmaceuticals' return on equity of -238.68% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CNS Pharmaceuticals beats Bio-Path on 10 of the 13 factors compared between the two stocks.

How does Bio-Path compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Xenetic Biosciences had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Xenetic Biosciences and 0 mentions for Bio-Path. Xenetic Biosciences' average media sentiment score of 0.44 beat Bio-Path's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Bio-Path	Neutral

Xenetic Biosciences has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market.

Xenetic Biosciences has higher revenue and earnings than Bio-Path. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.49	-$2.68M	-$1.20	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Bio-Path has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Bio-Path	N/A	-2,842.40%	-337.48%

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Xenetic Biosciences beats Bio-Path on 10 of the 13 factors compared between the two stocks.

How does Bio-Path compare to TNF Pharmaceuticals?

TNF Pharmaceuticals (NASDAQ:TNFA) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

TNF Pharmaceuticals' return on equity of -69.21% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Bio-Path	N/A	-2,842.40%	-337.48%

Bio-Path is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, TNF Pharmaceuticals had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for TNF Pharmaceuticals and 0 mentions for Bio-Path. TNF Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
TNF Pharmaceuticals	Neutral
Bio-Path	Neutral

Summary

TNF Pharmaceuticals beats Bio-Path on 7 of the 10 factors compared between the two stocks.

How does Bio-Path compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Acurx Pharmaceuticals currently has a consensus price target of $31.00, suggesting a potential upside of 1,756.29%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market.

In the previous week, Acurx Pharmaceuticals had 4 more articles in the media than Bio-Path. MarketBeat recorded 4 mentions for Acurx Pharmaceuticals and 0 mentions for Bio-Path. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat Bio-Path's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acurx Pharmaceuticals	Positive
Bio-Path	Neutral

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Acurx Pharmaceuticals' return on equity of -153.92% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Bio-Path	N/A	-2,842.40%	-337.48%

Summary

Acurx Pharmaceuticals beats Bio-Path on 10 of the 13 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.91M	$969.75M	$6.50B	$12.32B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	-0.03	1.47	24.00	24.65
Price / Sales	N/A	126.42	543.88	171.03
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	0.05	7.98	10.73	6.84
Net Income	-$16.08M	-$4.88M	$3.56B	$337.45M
7 Day Performance	N/A	3.60%	1.34%	2.48%
1 Month Performance	N/A	3.24%	2.25%	4.36%
1 Year Performance	N/A	47.52%	26.20%	32.45%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.04 flat	N/A	-79.7%	$1.91M	N/A	N/A	10	Gap Down High Trading Volume
ADXN Addex Therapeutics	0.5109 of 5 stars	$6.79 +15.9%	N/A	-21.8%	$7.22M	$210K	N/A	30	Gap Up
CNSP CNS Pharmaceuticals	3.0072 of 5 stars	$4.59 -6.1%	$20.00 +335.7%	-49.5%	$7.15M	N/A	N/A	5	Positive News Short Interest Increase
XBIO Xenetic Biosciences	0.601 of 5 stars	$3.08 -0.3%	N/A	+2.9%	$7.08M	$2.98M	N/A	4	Short Interest Increase
TNFA TNF Pharmaceuticals	0.0221 of 5 stars	$3.78 +1.9%	N/A	-71.8%	$6.98M	N/A	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors

BPTH vs. ADXN, CNSP, XBIO, TNFA, and ACXP

How does Bio-Path compare to Addex Therapeutics?

Summary

How does Bio-Path compare to CNS Pharmaceuticals?

Summary

How does Bio-Path compare to Xenetic Biosciences?

Summary

How does Bio-Path compare to TNF Pharmaceuticals?

Summary

How does Bio-Path compare to Acurx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Path (BPTH) Competitors

BPTH vs. ADXN, CNSP, XBIO, TNFA, and ACXP

How does Bio-Path compare to Addex Therapeutics?

Does the media prefer ADXN or BPTH?

Is ADXN or BPTH more profitable?

Do analysts prefer ADXN or BPTH?

Which has more volatility & risk, ADXN or BPTH?

Do insiders and institutionals have more ownership in ADXN or BPTH?

Which has better earnings and valuation, ADXN or BPTH?

Summary

How does Bio-Path compare to CNS Pharmaceuticals?

Which has more volatility and risk, BPTH or CNSP?

Does the media refer more to BPTH or CNSP?

Do analysts prefer BPTH or CNSP?

Which has stronger valuation & earnings, BPTH or CNSP?

Is BPTH or CNSP more profitable?

Do insiders & institutionals hold more shares of BPTH or CNSP?

Summary

How does Bio-Path compare to Xenetic Biosciences?

Does the media prefer XBIO or BPTH?

Which has more risk & volatility, XBIO or BPTH?

Which has preferable valuation and earnings, XBIO or BPTH?

Is XBIO or BPTH more profitable?

Do insiders and institutionals believe in XBIO or BPTH?

Do analysts prefer XBIO or BPTH?

Summary

How does Bio-Path compare to TNF Pharmaceuticals?

Is TNFA or BPTH more profitable?

Which has higher valuation and earnings, TNFA or BPTH?

Which has more volatility & risk, TNFA or BPTH?

Do analysts prefer TNFA or BPTH?

Do institutionals and insiders have more ownership in TNFA or BPTH?

Does the media refer more to TNFA or BPTH?

Summary

How does Bio-Path compare to Acurx Pharmaceuticals?

Do analysts prefer ACXP or BPTH?

Which has more risk & volatility, ACXP or BPTH?

Does the media prefer ACXP or BPTH?

Which has stronger earnings and valuation, ACXP or BPTH?

Do insiders & institutionals have more ownership in ACXP or BPTH?

Is ACXP or BPTH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools